Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 15, 2023 08:03 ET | Source: Research and Markets

Global Idiopathic Pulmonary Fibrosis Market Report 2023: Sector is Expected to Reach $7.52 Billion by 2030 at a CAGR of 8.7%

Dublin, June 15, 2023 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Market, By Drug, By Route of Administration, By Distribution Channel, and By Geography - Size, Share, Outlook, and...
April 25, 2022 07:08 ET | Source: Research and Markets

The Worldwide Idiopathic Pulmonary Fibrosis Industry is Expected to Reach $4.7 Billion by 2027

Dublin, April 25, 2022 (GLOBE NEWSWIRE) -- The "Global Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail...
February 28, 2022 06:23 ET | Source: Research and Markets

Global Idiopathic Pulmonary Fibrosis (IPF) Industry Forecast, 2030 - Competitive Landscape Assessment, Product Development & Innovation, Case Reports, Marketed Products & Emerging Therapies

Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to ResearchAndMarkets.com's...
January 20, 2022 04:43 ET | Source: Research and Markets

Global Idiopathic Pulmonary Fibrosis (IPF) Market Report 2021: Market was Valued at $3271.3 Million in 2020 - Forecast to 2026

Dublin, Jan. 20, 2022 (GLOBE NEWSWIRE) -- The "Global Idiopathic Pulmonary Fibrosis (IPF) Market - Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline...
July 13, 2021 05:13 ET | Source: Research and Markets

Idiopathic Pulmonary Fibrosis (IPF) Clinical Landscape Report 2021 with 10-Year Disease Incidence and Prevalence Forecasts

Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Idiopathic pulmonary fibrosis (IPF)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers...
December 30, 2020 08:58 ET | Source: Research and Markets

Esbriet (Pirfenidone): An Oral Anti-fibrotic Medicine Approved for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) - Global Drug Insight and Market Forecasts, 2017-2030

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Esbriet (Pirfenidone) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Esbriet (pirfenidone) -...
December 30, 2014 14:05 ET | Source: Coalition for Pulmonary Fibrosis (CPF)

CPF Celebrates Historic Year of Progress in Pulmonary Fibrosis

CULVER CITY, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) played an important role in much of the year's successes in Pulmonary Fibrosis (PF), helping to make...